Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Journal of Inflammation Research|May 18, 2026
Astragalus membranaceus and Salvia miltiorrhiza Inhibit Tryptase/PAR2-Mediated Mast Cells - Peritoneal Mesothelial Cells Crosstalk to Ameliorate Peritoneal FibrosisYanlin Chen, Yuqing Wu, Chenghua Zhang, et al.International Urology and Nephrology|March 11, 2024
Comparison of the applicability of seven calculation equations of glomerular filtration rate among elderly people in ChinaWeiwei Zhu, Yingyu Zhang, Shutao Chen, et al.Frontiers in Medicine|June 15, 2026
Acute kidney injury following household pyrethroid aerosol insecticide exposure: a case report and literature reviewYuxin Tang, Yuqing Wu, Xuhang Xue, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 15, 2011
Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinibRoman Casciano, Maruit Chulikavit, Giuseppe Di Lorenzo, et al.International Journal of Environmental Health Research|April 20, 2026
Molecular mechanisms of pyrethroid insecticide-induced acute kidney injury: a network toxicology and molecular docking analysisXuhang Xue, Yuqing Wu, Pei Sheng, et al.World Journal of Gastroenterology|April 25, 2013
United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatmentJonathan Strosberg, Roman Casciano, Lee Stern, et al.Pancreas|January 30, 2013
International practice patterns and resource utilization in the treatment of neuroendocrine tumorsRoman Casciano, Xufang Wang, Lee Stern, et al.Expert Opinion on Pharmacotherapy|May 24, 2011
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samplesGiuseppe Di Lorenzo, Roman Casciano, Elisabetta Malangone, et al.Journal of Medical Economics|November 26, 2014
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the USAllison Perrin, Steven Sherman, Sumanta Pal, et al.Current Medical Research and Opinion|December 17, 2013
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record reviewMichael K Wong, Hongbo Yang, James E Signorovitch, et al.Pageof 6